Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STERIMGLI: Hypofractionated SRT + Durvalumab in Recurrent Glioblastoma
2024-515000-39-00Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in glioblastoma (GBM) (2 arms), sponsored by Institut Claudius Regaud. Started Aug 2024; status: completed.
02
Drugs
durvalumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-515000-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515000-39-00.